Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Opioid Use Disorder Topic Center

Featured

nursing home care
News
CYP2D6-Metabolized Opioids and Antidepressant Concomitant Use Increases Adverse Events in Nursing Home Residents
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
FDA building sign
News
FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
News
When Cost Sharing Increases, More Naloxone Prescriptions Go Unfilled
07/10/2024
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due...
07/10/2024
Psych Congress Network
an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
four college students walking down a hall together
News
Adolescents and Young Adults Willing to Intervene During Overdose but Lack Naloxone Knowledge
06/11/2024
Brionna Mendoza
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of...
06/11/2024
Psych Congress Network
brain health
News
Rapid Procedural Approach Increases Opioid Treatment Initiation but Faces Resource Challenges
05/23/2024
Brionna Mendoza
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach...
05/23/2024
Psych Congress Network
News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Brionna Mendoza
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
rx summit
News
RX Summit Presenters Embrace Harm Reduction for Recovery-Ready Communities
04/09/2024
Jolynn Tumolo
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for...
04/09/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Jolynn Tumolo
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
From Addiction Professional
News
Study Finds No Significant Link Between Cannabis Use and Relapse in OUD Patients
01/26/2024

Tom Valentino

Tom Valentino
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10...
01/26/2024
Addiction Professional
From Addiction Professional

Advertisement

News

nursing home care
News
CYP2D6-Metabolized Opioids and Antidepressant Concomitant Use Increases Adverse Events in Nursing Home Residents
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
FDA building sign
News
FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
News
When Cost Sharing Increases, More Naloxone Prescriptions Go Unfilled
07/10/2024
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due...
07/10/2024
Psych Congress Network
four college students walking down a hall together
News
Adolescents and Young Adults Willing to Intervene During Overdose but Lack Naloxone Knowledge
06/11/2024
Brionna Mendoza
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of...
06/11/2024
Psych Congress Network
brain health
News
Rapid Procedural Approach Increases Opioid Treatment Initiation but Faces Resource Challenges
05/23/2024
Brionna Mendoza
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach...
05/23/2024
Psych Congress Network
News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Brionna Mendoza
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
rx summit
News
RX Summit Presenters Embrace Harm Reduction for Recovery-Ready Communities
04/09/2024
Jolynn Tumolo
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for...
04/09/2024
Psychiatry & Behavioral Health
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Jolynn Tumolo
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
News
Study Finds No Significant Link Between Cannabis Use and Relapse in OUD Patients
01/26/2024

Tom Valentino

Tom Valentino
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10 longitudinal studies conducted by Yale University researchers found no significant link between cannabis use and relapse on non-medical opioids among patients receiving medication-assisted treatment for opioid use...
A recent meta-analysis of 10...
01/26/2024
Addiction Professional
A health care professional reviews paperwork while sitting at a desk in front of a computer
News
Added Remote Support for Antidepressant Discontinuation Offers Only Small Benefits
08/07/2024
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone...
08/07/2024
Psych Congress Network
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
News
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
08/05/2024
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies...
08/05/2024
Psych Congress Network
nursing home care
News
CYP2D6-Metabolized Opioids and Antidepressant Concomitant Use Increases Adverse Events in Nursing Home Residents
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
A brain puzzle against an orange background
News
Most Patients With Schizophrenia Relapse-Free With Paliperidone Palmitate, Open Label Extension Study Finds
08/01/2024
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension...
08/01/2024
Psych Congress Network
Doctor and patient
News
Clinician-Level Differences Significantly Affect MDD Prescribing, Outcomes
08/01/2024
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
News
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
07/31/2024
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid...
07/31/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
FDA building sign
News
FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
One in 7 Patients Experience Antidepressant Discontinuation Symptoms, Study Says
News
One in 7 Patients Experience Antidepressant Discontinuation Symptoms, Study Says
07/22/2024
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects,...
07/22/2024
Psych Congress Network

Quizzes

an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
quiz
Quiz
What role does norepinephrine play in bipolar disorder symptom presentation?
08/07/2024
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do...
08/07/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Expert Insights Quiz
HIPPA Considerations for Social Media
07/22/2024
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice...
07/22/2024
Psych Congress Network
How many symptoms must be present in order to diagnose adult ADHD?
Quiz
How many symptoms must be present in order to diagnose adult ADHD?
07/17/2024
Challenge your diagnostic knowledge!
Challenge your diagnostic knowledge!
Challenge your diagnostic...
07/17/2024
Psych Congress Network
How easy is it to switch patients from olanzapine to olanzapine samidorphan?
Quiz
How easy is it to switch patients from olanzapine to olanzapine samidorphan?
07/16/2024
Do you remember this insight from Dr Jain?
Do you remember this insight from Dr Jain?
Do you remember this insight...
07/16/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
A cartoon illustration of a brain with two medical professionals standing on either side; one holds up a magnifying glass to the brain
Quiz
Differences in ADHD Symptoms Due to Sex
07/02/2024
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR...
07/02/2024
Psych Congress Network
quiz
Quiz
Which factor is NOT consideration when choosing an antidepressant medication?
06/28/2024
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a...
06/28/2024
Psych Congress Network
quiz
Quiz
Which symptoms of schizophrenia must be present to make a diagnosis?
06/21/2024
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic...
06/21/2024
Psych Congress Network
an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
Can stimulant use increase risk of heart damage in young adults with ADHD?
Quiz
Can stimulant use increase risk of heart damage in young adults with ADHD?
06/17/2024
Time for a pop quiz!
Time for a pop quiz!
Time for a pop quiz!
06/17/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement